儿童格雷夫斯病的流行病学及治疗

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (401 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Graves disease is a common autoimmune disease with unknown pathogenesis. The incidence of children is significantly lower than that of adults, the incidence varies from place to place, but the overall trend is increasing year by year. The most common laboratory test is the change of thyroid function, and the clinical manifestations include hypermetabolism symptoms and other manifestations such as accelerated growth. At present, oral Methimazole is the first choice for the treatment of children with Graves disease, which is convenient to treat and has few adverse reactions. For children who have not improved after long-term oral antithyroid drug treatment, iodine therapy can be considered, which will significantly improve the remission rate of children. This article reviews the status of Graves disease in children.

Key words： Graves disease Epidemiology Methimazole Radioactive iodine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHI Hongjiao ZHANG Yili ZHAO Tong CUI Lanwei

Cite this article:

SHI Hongjiao ZHANG Yili ZHAO Tong CUI Lanwei. Epidemiology and treatment status of Graves disease in children[J]. 中国医药导报, 2022, 19(22): 39-41.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I22/39

[1] Committee on Pharmaceutical Affairs，Japanese Society for Pediatric Endocrinology，and the Pediatric Thyroid Disease Committee，Japan Thyroid Association （Taskforce for the Revision of the Guidelines for the Treatment of Childhood-Onset Graves’ Disease）. Guidelines for the treatment of childhood-onset Graves’ disease in Japan，2016 [J]. Clin Pediatr Endocrinol，2017，26（2）：29-62.
[2] Smith TJ，Hegedüs L. Graves’ Disease [J]. N Engl J Med，2016，375（16）：1552-1565.
[3] Simon M，Rigou A，Le Moal J，et al. Epidemiology of Childhood Hyperthyroidism in France：A Nationwide Population-Based Study [J]. J Clin Endocrinol Metab，2018，103（8）：2980-2987.
[4] Lavard L，Ranl?覬v I，Perrild H，et al. Incidence of juvenile thyrotoxicosis in Denmark，1982-1988. A nationwide study [J]. Eur J Endocrinol，1994，130（6）：565-568.
[5] Havgaard Kj?覸r R，Smedeg?覽rd Andersen M，Hansen D. Increasing Incidence of Juvenile Thyrotoxicosis in Denmark：A Nationwide Study，1998-2012 [J]. Horm Res Paediatr，2015，84（2）：102-107.
[6] Rodanaki M，Lodefalk M，Forssell K，et al. The Incidence of Childhood Thyrotoxicosis Is Increasing in Both Girls and Boys in Sweden [J]. Horm Res Paediatr，2019，91（3）：195-202.
[7] Forssberg M，Arvidsson CG，Engvall J，et al. Increasing incidence of childhood thyrotoxicosis in a population-based area of central Sweden [J]. Acta Paediatr，2004，93（1）：25-29.
[8] Wong GW，Kwok MY，Ou Y. High incidence of juvenile Graves’ disease in Hong Kong [J]. Clin Endocrinol （Oxf），1995，43（6）：697-700.
[9] Wong GW，Cheng PS. Increasing incidence of childhood Graves’disease in Hong Kong：a follow-up study[J]. Clin Endocrinol （Oxf），2001，54（4）：547-550.
[10] 袁琳，李贤坤，刘春桃，等.儿童与成人格雷夫斯病的临床比较[J].中国实用儿科杂志，2004，19（6）：367-368.
[11] 夏秦，陈临琪，陈婷.儿童自身免疫性甲状腺疾病发病机制的研究进展[J].医学综述，2021，27（3）：428-435，441.
[12] Srinivasan S，Misra M. Hyperthyroidism in children [J]. Pediatr Rev，2015，36（6）：239-248.
[13] Choi HY，Jung JH，Ahn JH. Comparison of Orbital Pread-ipocyte Adipogenesis Between Pediatric and Adult Graves Ophthalmopathy [J]. J Craniofac Surg，2020，31（3）：727-730.
[14] 徐海波.二维超声与彩色多普勒超声在桥本氏甲状腺炎与甲状腺功能亢进症鉴别诊断中的应用价值[J].现代医学与健康研究电子杂志，2021，5（4）：124-126.
[15] 马晓丹，毛晓健，刘丽，等.甲状腺功能亢进症患儿393例肝损害相关因素分析[J].中华实用儿科临床杂志，2015， 30（8）：597-599.
[16] 姜含芳，黄晶，黄宝兴，等.甲状腺功能亢进患儿的血尿酸水平变化分析[J].检验医学与临床，2019，16（4）：526-528.
[17] 龚雪萍，江颖慧，冉启锋.儿童甲状腺功能亢进症血脂、血糖水平在甲状腺激素与心率间的中介作用[J].中国医学创新，2021，18（20）：143-146.
[18] Yoshihara A，Luo Y，Ishido Y，et al. Inhibitory effects of methimazole and propylthiouracil on iodotyrosine deiodinase 1 in thyrocytes [J]. Endocr J，2019，66（4）：349-357.
[19] Bahn Chair RS，Burch HB，Cooper DS，et al. American Thyroid Association；American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis：management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists [J]. Thyroid，2011，21（6）：593-646.
[20] Maia AL，Scheffel RS，Meyer EL，et al. Brazilian Society of Endocrinology and Metabolism. The Brazilian consensus for the diagnosis and treatment of hyperthyroidism：recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism [J]. Arq Bras Endocrinol Metabol，2013，57（3）：205-232.
[21] 陈晓波，宋福英.儿童甲状腺功能亢进症的诊断、治疗及预后[J].中华实用儿科临床杂志，2019，34（8）：561-564.
[22] 宋荣华，张进安.青少年甲状腺疾病的特点和管理[J].中国实用内科杂志，2021，41（2）：107-111.
[23] Kahaly GJ，Bartalena L，Hegedüs L，et al. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism [J]. Eur Thyroid J，2018，7（4）：167-186.
[24] 冷斐，陆志强.儿童和青少年甲状腺功能亢进的治疗[J].上海医药，2015，36（7）：6-11.
[25] Sato H，Minagawa M，Sasaki N，et al. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves’ disease：efficacy and adverse reactions during initial treatment and long-term outcome [J]. J Pediatr Endocrinol Metab，2011，24（5/6）：257-263.
[26] Gu Y，Liang X，Liu M，et al. Clinical features and predictors of remission in children under the age of 7 years with Graves’ disease [J]. Pediatr Investig，2020，4（3）：198-203.
[27] Sato H，Sasaki N，Minamitani K，et al. Higher dose of methimazole causes frequent adverse effects in the management of Graves’disease in children and adolescents [J]. J Pediatr Endocrinol Metab，2012，25（9/10）：863-867.
[28] 中华医学会核医学分会.131I治疗格雷夫斯甲亢指南（2021版）[J].中华核医学与分子影像杂志，2021，41（4）：242-253.
[29] 卢桂南.131I治疗儿童及青少年Graves病甲亢疗效评价[J].内科，2016，11（6）：897-898，933.
[30] 杨凡慧，陈跃，张春银.131I治疗青少年及儿童格雷夫斯甲亢的临床应用随访研究[J].国际放射医学核医学杂志，2017，41（2）：98-102.